Compare Moderna, Inc. (MRNA) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.

SPUS trades at $56.32, down 0.23% on the day, with a bearish technical outlook from moving averages and oscillators. Key support is at $56, with resistance at $57. The stock's financial ratios, including P/E and P/S, are not available in the provided data. Recent corporate actions include small dividend payments scheduled for mid-2026, indicating a shareholder return focus.

The outlook for SPUS is cautious due to weak technical signals and limited fundamental data visibility. Investment opportunities may lie in its dividend strategy, but risks include market volatility and lack of current financial metrics. Investors should seek updated earnings reports for a clearer fundamental picture before considering a position.